1. Claim 1: a can medicine intermediate device (1) in the formula,where X⁻ ⁻Y is selected from CH₂-CH₂,CH = CH, C (= O) -NH or CH₂-NH； A is a 5-membered or 6-membered heterocyclic ring, optionally substituted with a group selected from F, C₁₋₆-alkyl or = C (R) ₂,where R is independently selected from H, F, C₁₋₆ alkyl or C₁₋₆ fluoroalkyl；R¹ and R² are independently selected from H or C₁₋₆ alkyl or R alqu and R² form a 3-, 4-, 5- or 6-membered heterocyclic or cycloalkyl group, R³ is independently selected from NO₂,CL, F, CN, co8322； h or BR and m are equal to 0, 1 or 2. Claim 11: a compound antibody drug in a formula (2),O select the acceptable salt of X 8315； - 8315y and ch83228c；CH -C (3DO)Ch = ch o c833222h-nh； a is a heterocyclic ring composed of 5 or 6 members, which can be replaced by a group of F, tar c833318326o = C (R) 832222；where R is independently selected from H, F, C₁₋₆ alkyl or C₁₋₆ fluoroalkyl,R¹ and R² are independently selected from H or C₁₋₆ alkyl or R¹ and R² form a 3-, 4-, 5-, or 6-membered heterocyclic or cycloalkyl group, p is an integer from 1 to 8, and Ab is an antibody. Claim 71: An antibody-drug conjugate, or a pharmaceutically acceptable salt thereof, of formula (3) wherein Ab is a cysteine modified anti-HER2 antibody comprising LC K149C and p is about 2.Reivindicación 1: Un intermedio enlazador-fármaco de la fórmula (1), en la que X⁻ ⁻Y se selecciona de CH₂-CH₂, CH=CH, C(=O)-NH o CH₂-NH； A es un anillo heterocíclico de 5 miembros o 6 miembros, opcionalmente sustituido con un grupo seleccionado de F, alquilo C₁₋₆ o =C(R)₂, donde R se selecciona independientemente de H, F, alquilo C₁₋₆ o fluoroalquilo C₁₋₆； R¹ y R² se seleccionan independientemente de H o alquilo C₁₋₆ o R¹ y R² forman un grupo heterocíclico o cicloalquilo de 3, 4, 5 ó 6 miembros, R³ se selecciona independientemente de NO₂, Cl, F, CN, CO₂H o Br y m es 0, 1 ó 2. Reivindicación 11: Un compuesto conjugado de anticuerpo-fármaco de la fórmula (2), o una sal farmacéuticamente acept
